

MoleculeX Analysis Report

AI-Driven Pharmaceutical Insight Discovery

Job ID: a056511b-285a-4dff-9039-483f04d18d95

Query

Find unmet medical needs in oncology with recent patent activity

Executive Summary

Analysis of recent patent activity in oncology reveals unmet medical needs, particularly within the areas of PD-1 antibody formulations and CAR-T cell therapies. Despite a lack of ongoing clinical trials, significant intellectual property investment suggests considerable market potential and ongoing research interest in these areas. Further investigation is required to fully understand the competitive landscape and specific clinical applications representing the most promising investment opportunities.

Key Findings

- Analysis Confidence: Medium (1/100) - Based on 0 trials, 8 patents, 20 publications
- Competitive Analysis: Unknown competition detected with 0 active trials
- Patent Landscape: 8 relevant patents identified, 0 currently active

Clinical Trials Overview

0

Total Trials

0

Active Trials

UNKNOWN

Competition Level

Patent Landscape

■■ Legal Disclaimer - Freedom to Operate (FTO)

Important: The patent information provided in this report is for research and informational purposes only and does not constitute legal advice. This analysis does not represent a comprehensive Freedom-to-Operate (FTO) search or opinion.

Before commercialization: Consult with qualified patent attorneys to conduct a thorough FTO analysis, assess potential infringement risks, and develop appropriate IP strategies. Patent landscapes are complex and require expert legal interpretation.

US10675289B2	PD-1 antibody formulations for cancer immunotherap...	Bristol-Myers Squibb Company	2020-06-09	Granted

US10751349B2	CAR-T cell therapies for hematologic malignancies...	Novartis AG	2020-08-25	Granted
US11129822B2	BRAF and MEK inhibitor combinations for melanoma t...	Merck & Co.	2021-09-28	Granted
US10633411B2	Pharmaceutical compositions containing EGFR inhibi...	AstraZeneca AB	2019-04-25	Granted
US11180517B2	SGLT2 inhibitor combinations for diabetes and card...	Boehringer Ingelheim	2021-11-23	Granted
US10912783B2	GLP-1 receptor agonist delivery systems for obesit...	Novo Nordisk A/S	2021-02-09	Granted
US10557109B2	JAK inhibitor formulations for treatment of inflam...	Pfizer Inc.	2020-02-11	Granted
US11098065B2	CFTR modulator combinations for cystic fibrosis...	Vertex Pharmaceuticals	2021-08-24	Granted

Web Intelligence

--	--	--	--

MED	Targeting autophagy in cancer....	100%	Autophagy is a mechanism by which cellular material is delivered to lysosomes fo...
MED	Triple-negative breast cancer: challenge...	100%	Chemotherapy is the primary established systemic treatment for patients with tri...
MED	Adoptive cell transfer as personalized i...	100%	Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involve...
MED	Intraepithelial CD8+ tumor-infiltrating ...	100%	In a recent report, [Zhang et al. (2003) N. Engl. J. Med. 348, 203-213], the pre...
MED	Molecular and genetic properties of tumo...	100%	How the genomic landscape of a tumor shapes and is shaped by anti-tumor immunity...
MED	Personalizing the treatment of women wit...	100%	The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel re...
MED	Human papillomavirus and rising orophary...	100%	<h4>Purpose</h4>Recent increases in incidence and survival of oropharyngeal canc...
MED	Photodynamic therapy of cancer: an updat...	100%	Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeu...

This report is for informational purposes only and should not be considered as medical or investment advice.